The website does not constitute a distribution, an offer or solicitation of an offer to buy or sell any interest in any securities or other investment product managed or arranged by Chartwell Capital Limited (H.K.) or any of its affiliates. The information contained herein is current as at the date of publication and is subject to change without any notice. No representation or warranty, expressed or implied, is made to the accuracy, completeness or thoroughness of the contents, and no liability whatsoever is accepted by Chartwell Capital Limited (H.K.) or any of its affiliates. The material contained herein may not be reproduced, distributed or published without the prior consent of Chartwell Capital Limited (H.K.). If you are in any doubt about any of the information contained herein you should consult your own investment advisor, lawyer, accountant or other professional advisers.
By clicking proceed, I declare that I reside outside Hong Kong or at a location in Hong Kong but am a professional investor.
Investors
Chartwell Capital Limited is an investment company licensed to undertake Asset Management and Advising on Securities by the Hong Kong Securities and Futures Commission (SFC). The Company provides its services solely to Professional Investors (PIs), as defined by the Securities and Futures Ordinance.

As an investor with Chartwell Capital, you will be aware that we engage positively with the management of companies we invest in. We are keen to help them generate value for shareholders, champion industry change and improve corporate governance. This includes both on-going dialogue and formal communication – which for transparency we give you full access to below:

Alphamab Oncology (9966:HK)
Chartwell’s letter to Alphamab Oncology – July 2, 2021

CMGE Technology Group Limited (302:HK)
Chartwell’s letter to CMGE Technology – December 2, 2021
CMGE’s response to Chartwell – December 5, 2021

COSCO Shipping International (517:HK)
Chartwell’s letter to COSCO Shipping – August 21, 2020
COSCO Shipping’s response to Chartwell – September 3, 2020

EC Healthcare (2138:HK)
Chartwell’s letter to EC Healthcare – November 13, 2020
EC Healthcare’s response to Chartwell – December 8, 2020

Chartwell’s letter to EC Healthcare – April 20, 2022
EC Healthcare’s response to Chartwell – April 21, 2022

Far East Consortium (35:HK)
Chartwell’s letter to FEC – September 26, 2019
FEC’s response to Chartwell – November 29, 2019

FSE Services Group Ltd. (331:HK)
Chartwell’s letter to FSE – November 20, 2020
FSE’s response to Chartwell – November 25, 2020

Hua Hong Semiconductor Limited (1347:HK)
Chartwell’s letter to Hua Hong – June 11, 2020
Hua Hong’s response to Chartwell – July 29, 2020

Chartwell’s letter to Hua Hong – February 22, 2021
Hua Hong’s response to Chartwell – March 10, 2021

Chartwell’s letter to Hua Hong – November 3, 2021
大正资本致华虹半导体函件 – 2021年11月3日

NWS Holdings Limited (659:HK)
Chartwell’s letter to NWS – January 17, 2020
NWS’s response to Chartwell – March 4, 2020

Chartwell’s letter to NWS – October 9, 2020
NWS’s response to Chartwell – November 24, 2020

Chartwell’s letter to NWS – February 5, 2021
NWS’s response to Chartwell – February 10, 2021

Chartwell’s letter to NWS – August 18, 2021
NWS’s response to Chartwell – October 12, 2021

SF REIT (2191:HK)
Chartwell’s letter to SF REIT – November 3, 2021
SF REIT’s response to Chartwell – December 7, 2021

VTech Holdings Ltd. (303:HK)
Chartwell’s letter to VTech – May 5, 2021
VTech’s response to Chartwell – June 9, 2021

Copyright© Chartwell Capital Limited.
All rights reserved.